glp-1 receptor agonists in idiopathic intracranial hypertension glp 1 The effect of agonist on idiopathic Use of glucagon-like peptide-1 receptor

This includes trials of drug combinations such as Novo Nordisks CagriSema that combines semaglutide with investigational drug cagrilintide to improve efficacy

Firstly because of the abundance of GLP-1 receptors in the brain, and secondly because the brain and the immune system communicate with all organs in the body (Lunenfeld-Tanenbaum Research Institute)

Overexpression of glutamine:fructose-6-phosphate-amidotransferase induces transforming growth factor-beta1 synthesis in NIH-3T3 fibroblasts

Stringent cost and payer controls are a significant restraint in the GLP-1 drugs market due to the high prices associated with these therapies

Cardiovascular research

Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA